Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2021-10-07

Clinical Trial Update: Ibudilast and Withdrawal-Related Dysphoria [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating ibudilast for withdrawal-related dysphoria in alcohol use disorder has completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • ibudilast (ibudilast)

Snippet

Sponsor: University of California, Los Angeles | Conditions: Alcohol Use Disorder | Phase 2 | Status: COMPLETED | Results posted: 2021-10-07